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Analysis of positional candidate genes in the
AAA1 susceptibility locus for abdominal aortic
aneurysms on chromosome 19
John H Lillvis1, Yoshiki Kyo1,9, Gerard Tromp2, Guy M Lenk1,10, Ming Li3, Qing Lu3,4, Robert P Igo Jr4,
Natzi Sakalihasan5, Robert E Ferrell6, Charles M Schworer2, Zoran Gatalica7, Susan Land1,8, Helena Kuivaniemi2*
Abstract
Background: Abdominal aortic aneurysm (AAA) is a complex disorder with multiple genetic risk factors. Using
affected relative pair linkage analysis, we previously identified an AAA susceptibility locus on chromosome 19q13.
This locus has been designated as the AAA1 susceptibility locus in the Online Mendelian Inheritance in Man
(OMIM) database.
Methods: Nine candidate genes were selected from the AAA1 locus based on their function, as well as mRNA
expression levels in the aorta. A sample of 394 cases and 419 controls was genotyped for 41 SNPs located in or
around the selected nine candidate genes using the Illumina GoldenGate platform. Single marker and haplotype
analyses were performed. Three genes (CEBPG, PEPD and CD22) were selected for DNA sequencing based on the
association study results, and exonic regions were analyzed. Immunohistochemical staining of aortic tissue sections
from AAA and control individuals was carried out for the CD22 and PEPD proteins with specific antibodies.
Results: Several SNPs were nominally associated with AAA (p < 0.05). The SNPs with most significant p-values
were located near the CCAAT enhancer binding protein (CEBPG), peptidase D (PEPD), and CD22. Haplotype analysis
found a nominally associated 5-SNP haplotype in the CEBPG/PEPD locus, as well as a nominally associated 2-SNP
haplotype in the CD22 locus. DNA sequencing of the coding regions revealed no variation in CEBPG. Seven
sequence variants were identified in PEPD, including three not present in the NCBI SNP (dbSNP) database.
Sequencing of all 14 exons of CD22 identified 20 sequence variants, five of which were in the coding region and
six were in the 3’-untranslated region. Five variants were not present in dbSNP. Immunohistochemical staining for
CD22 revealed protein expression in lymphocytes present in the aneurysmal aortic wall only and no detectable
expression in control aorta. PEPD protein was expressed in fibroblasts and myofibroblasts in the media-adventitia
border in both aneurysmal and non-aneurysmal tissue samples.
Conclusions: Association testing of the functional positional candidate genes on the AAA1 locus on chromosome
19q13 demonstrated nominal association in three genes. PEPD and CD22 were considered the most promising
candidate genes for altering AAA risk, based on gene function, association evidence, gene expression, and protein
expression.
Background
Abdominal aortic aneurysm (AAA) is an irreversible,
progressive dilation of the abdominal aorta, occurring
most frequently below the renal arteries. Known risk
factors for AAA include smoking, male sex, comorbid
vascular disease, increasing age, and family history [1].
AAA pathophysiology is complex, but fundamentally
aneurysms arise from the loss of structural integrity and
the consequent weakening of the vessel wall. Several
extracellular matrix (ECM) degrading enzymes, includ-
ing matrix metallopeptidases (MMPs) [2], cathepsins
[3,4], and granzyme [5], have been implicated in the
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destruction and turnover of ECM proteins in the aortic
wall. Infiltrating cells of the immune system are also
found throughout the AAA wall [6] and are important
to AAA development by producing ECM degrading
enzymes and reactive oxygen species, as well as releasing
proinflammatory cytokines that lead to further inflam-
mation [7,8].
AAA also displays several characteristics consistent
with being a multifactorial genetic disease [9]. Approxi-
mately 15% of AAA patients have a positive family his-
tory [10] and genetic association studies have identified
risk alleles in cardiovascular risk genes such as DAB2IP
[11], CDKN2BAS [12], AGTR1 [13,14], ACE [13,14], and
MTHFR [14]. These polymorphisms, however, explain
only a small fraction of an individual’s genetic risk for
AAA. A genome-wide DNA linkage analysis using an
affected relative pair approach with covariates by our
laboratory identified two linked chromosomal regions on
19q13 and 4q31 [15]. Linkage to chromosome 19q was
replicated in a separate study in Dutch families using dif-
ferent statistical analyses [16]. Chromosome 19q13 may
harbour risk alleles for several aneurysm phenotypes, as
linkage to this region has also been reported for intracra-
nial aneurysms [17-19] and the Kawasaki disease [20].
Several functional candidate genes reside within the
chromosome 19 candidate interval. Peptidase D (PEPD;
prolidase) is a manganese-dependent dipeptidyl pepti-
dase that cleaves iminopeptides with C-terminal proline
or hydroxyproline, which is the terminal step in collagen
degradation [21]. The chromosome 19q candidate inter-
val also contains several genes that may be relevant to
immune system function in AAA. CD22 is a sialic-acid
binding protein expressed in B-lymphocytes, which can
inhibit signalling through the B-cell receptor and there-
fore alter B-cell function [22]. B-cells are found in the
AAA wall and CD22 has been implicated in autoim-
mune pathologies characterized by similar inflammatory
and ECM changes seen in some AAAs [23].
Here we report on an analysis of candidate genes
selected from the chromosome 19q13 linkage interval.
Nine functional positional candidate genes (PEPD,
CEBPA, CEBPG, GPI, HAMP, CD22, NFKBID, TYROBP,
and HCST) were identified as having annotated function
in either the immune system or in ECM turnover. Fifty-
five SNPs covering the major haplotype blocks in each
gene were selected. Two genes with evidence of associa-
tion, CD22 and PEPD, were investigated further by exon
sequencing and immunohistochemical staining of aneur-
ysmal and non-aneurysmal aortic tissue samples.
Methods
Human samples for genotyping
AAA cases used in genotyping (n = 394; 79% male) were
collected at the University of Pittsburgh, the University
of Liége in Liége, Belgium, and Dalhousie University
Hospital in Nova Scotia, Canada. Canadian controls
were spouses of AAA cases. Belgian controls were
patients with diagnoses other than AAA and treated at
the same hospital as the AAA cases. Details on the
recruitment have been published previously and the
samples have been used in prior genetic association stu-
dies [12,24,25]. The collection of samples was approved
by the Institutional Review Board of Wayne State
University and each recruitment site.
DNA isolation and whole genome amplification (WGA)
Genomic DNA used in genotyping and sequencing was
isolated from peripheral blood as described previously
[25]. A total of 10 ng of genomic DNA was amplified by
strand-displacement amplification [26] with Phi29 poly-
merase using the Genomiphi Kit (GE Healthcare Bios-
ciences, Piscataway, NJ) according to the manufacturer’s
instructions. Amplified DNA was diluted 1:100 for use
in genotyping and DNA sequencing reactions.
RNA isolation and cDNA synthesis
Total RNA was isolated from cultured skin fibroblasts as
previously described [27]. cDNA was prepared from
250 ng of RNA using SuperScript III First-Strand Synth-
esis Supermix (Invitrogen, Carlsbad, CA). Residual RNA
was removed by RNAse H treatment.
Genetic association study
Genes in the linkage interval on chromosome 19 were
prioritized functionally using Gene Ontology (GO) [28]
and Kyoto Encyclopedia of Genes and Genomes
(KEGG) [29] annotations. mRNA expression of each
gene in AAA and control abdominal aorta was also
assessed using data from a previously described microar-
ray-based mRNA expression profiling study [30]. Alto-
gether 55 SNPs with a minor allele frequency (MAF) of
0.10 or greater that were representative of major haplo-
type blocks in the Caucasian population were identified
in and around the nine positional functional candidate
genes selected for the study. Each SNP was assessed for
its SNP quality score from Illumina and a custom Illu-
mina BeadChip was designed using those SNPs consid-
ered to have sufficient designability. The SNPs are listed
in Additional file 1, Table S1.
Power calculations were performed using the Genetic
Power Calculator [31] (http://pngu.mgh.harvard.edu/
~purcell/gpc/). We assumed that the polymorphism and
the disease locus were in complete linkage disequili-
brium (LD) and that they had the same allele frequen-
cies, i.e., the polymorphism was the disease locus.
Assuming a disease locus with an additive effect and a
disease prevalence of 0.02, our sample size of 394 cases
and 419 controls had an 80% power to detect a
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susceptibility locus with a genotypic relative risk (GRR)
≥ 1.2 (2.4 for two copies of risk alleles) at a significance
level of 0.05 for a SNP with a high risk allele frequency
(HAF) ≥ 0.2.
SNPs were genotyped using the Illumina GoldenGate
assay [32] and the call rate of each SNP was evaluated
using GenCall Software (version 6.1.3.28, Illumina, San
Diego, CA). Deviation from Hardy-Weinberg equili-
brium (HWE) was evaluated using an exact test [33] as
implemented in Haploview [34] and nominal p-values
without correction for multiple testing are reported in
Additional File 1. Allelic association was tested using a
Pearson c2 test with one degree of freedom (DF). To
assess the potential for population stratification, HWE
and allelic association were also tested separately in the
Belgian and Canadian subpopulations. An additional test
of association was performed using the general linear
mixed model approach implemented in the Statistical
Analysis for Genetic Epidemiology (S.A.G.E.) [35] pro-
gram ASSOC, which yields both Wald and likelihood
ratio test (LRT) statistics. Both tests gave very similar
results and therefore, we report only results from the
LRT which is considered more robust in small sample
sizes. False discovery rates (FDR) are reported for the
LRT. Haplotype association was analyzed using a score
test [36] implemented in the haplo.score function in the
package HaploStats for the R statistical language and
environment [35]. For genes with evidence of associa-
tion, LD plots were generated from the case and control
genotypes separately using HaploView to examine LD
structure.
DNA sequencing of functional positional candidate genes
Genomic DNA and RNA samples used in DNA sequen-
cing are listed in Additional files 2 (Table S2) and
3 (Table S3). Primer pairs to amplify the coding
sequence of CEBPG, cDNA sequence of PEPD, and exo-
nic sequences of CD22 were designed using Primer-
QuestSM, a primer design tool based on Primer3
software [37] available on the Integrated DNA Technol-
ogies website (http://www.idtdna.com/Scitools/Applica-
tions/Primerquest/; IDT, Coralville, IA). Primers were
selected using predicted melting points, primer hairpins
and primer-dimer interactions calculated using the Sci-
Tools programs in PrimerQuestSM. DNA amplification
by PCR was performed under the following conditions.
Final concentrations were 50 mM KCl, 1.5 or 2 mM
MgCl2 (primer-pair specific; see Additional file 4, Table
S4), 2 μM dNTPs, 0.167 μM of each primer, 0.025 U/μl
AmpliTaq Gold enzyme (Applied Biosystems) in 10 mM
Tris-HCl, pH 8.3. Template DNA constituted 1/10th of
the final volume for WGA-genomic DNA or 1/20th for
cDNA. Template was denatured by heating to 94°C for
10 minutes, which was followed by 40 cycles of
denaturation (94°C), annealing (variable) and elongation
(72°C), and a final three-minute elongation incubation
at 72°C. Detailed cycle times and annealing tempera-
tures are found in Additional file 4, Table S4.
PCR products were separated by agarose gel electro-
phoresis to assess the sizes of bands and the specificity
of the reaction. PCR products with single clean bands of
the correct molecular weight were purified for DNA
sequencing using Montage™ PCR purification columns
(Millipore, Billerica, MA).
DNA sequencing was performed using the Cycle
Sequencing (Applied Biosystems, Foster City, CA)
method at the Applied Genomics Technology Center
(AGTC) at Wayne State University. Primers used for
DNA sequencing can be found in Additional file 5,
Table S5. Sequence variants were identified by align-
ment of sequences using BioX software (available at
https://www.lagercrantz.name/projects/biox) and manual
examination of the sequence plots.
Functional analysis of sequence variants
To assess the potential function of identified sequence
variants, in silico functional analyses were carried out.
The SIFT (Sorting Intolerant from Tolerant) algorithm
[38] was used to predict the structural effects of non-
synonymous substitutions. NetPhos [39] was used to
predict the creation or destruction of phosphorylation
sites. To assess the potential effect of 3’-untranslated
region (UTR) sequence variants on microRNA (miRNA)
binding, predicted binding sites were obtained from the
MicroCosm Targets Database [40,41] (http://www.ebi.ac.
uk/enright-srv/microcosm/htdocs/targets/v5/).
Immunohistochemical staining to analyze protein
expression in human aortic tissues
Control non-aneurysmal aortas (n = 7) were obtained
post-mortem at autopsy. Exclusion criteria were known
malignancy or systemic infection. AAA tissues (n = 9)
were obtained from elective surgical repair operations
when the aneurysmal sac was trimmed as part of sur-
gery. Tissue samples were removed solely for the pur-
pose of graft placement and would otherwise be
discarded. Tonsil (for CD22) or kidney (for PEPD) tissue
were used as positive controls. Nonspecific IgG in lieu
of primary antibody served as a negative control. All tis-
sue samples were fixed in buffered formalin solution,
routinely processed and then embedded in paraffin.
Details on aortic samples used can be found in Addi-
tional file 6: Table S6.
Immunohistochemical staining was carried out using
5 μm sections of formalin-fixed paraffin embedded aor-
tic tissue. Sections were dried in an oven and deparaffi-
nized using sequential rinses in Histoclear xylene
substitute (National Diagnostics U.S.A., Atlanta, GA),
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100% ethanol, 95% ethanol and water. Heat-induced
antigen retrieval was performed by microwave-treatment
of slides submerged in citrate buffer. Endogenous perox-
idase was blocked by placing slides in 3% methanol/per-
oxide block solution for 10 min. The slides were
incubated with primary antibody directed against PEPD
(1:250 dilution; catalog number 12218-1-AP, Proteintech
Group, Inc., Chicago, IL) or CD22 (1:100 dilution; cata-
log number ab953, Abcam Inc., Cambridge, MA) on an
automatic immunostainer (Autostainer, DAKO, Carpin-
teria, CA). A secondary antibody with avidin-biotin per-
oxidase amplification from DAKO was used and the
signal detected using diaminobenzidine as a chromogen.
Results
Selection of functional candidate genes on AAA1 locus
The AAA1 linkage interval (Figure 1) spans approximately
4 Mbp from 33 Mbp to 37 Mbp (NCBI build 37.3) on chro-
mosome 19q13 and contains over 100 genes. In order to
identify a smaller set of strong candidate genes for further
study, GO and KEGG functional annotations were used to
identify nine genes with functions relevant to AAA patho-
genesis (Table 1). Eight of these genes were selected based
on an annotated function in the immune system, as immune
involvement in AAA pathogenesis has been well studied [7].
Additionally, PEPD, was identified as a candidate gene based
on its activity in collagen turnover and potential for contri-
buting to ECM remodelling in the AAA wall [21].
Since genes not expressed in aortic tissue, either dis-
eased or non-diseased, would be less likely to contribute
to aneurysm formation, mRNA expression of each can-
didate gene was assessed using microarray expression
profiles of AAA and control aortic tissue. As all of the
genes selected by functional annotation were expressed
in either AAA or control abdominal aorta, no genes
were excluded by this criterion. Furthermore, four of
these genes, CEBPA, NFKBID, HCST and TYROBP, had
significantly higher expression in AAA tissue than in
age-, sex-, and ethnicity-matched control aortas and
CD22 was expressed only in AAA tissue (Table 1).
Candidate gene association study
Fifty-five SNPs in or around the nine functional candi-
date genes found in the AAA1 locus were genotyped.
Eleven SNPs were excluded from further analysis since
they were either monomorphic or had low genotype call
rates (Additional file 1, Table S1). This number can be
considered high, but is expected in a custom array
where several of the SNP assays had not been previously
validated. Additionally, the excluded SNPs were located
in CEPBA and PEPD, where the genotyping coverage
was excellent even without including the failed assays.
Testing for deviation from HWE was performed in the
remaining 44 SNPs and four SNPs (rs7248389,
rs752237, rs736289 and rs4239576) that showed devia-
tion were identified (Additional file 1, Table S1). One of
the four SNPs also showed evidence of association and
since deviation from HWE can result from association,
this SNP (rs7248389) was included in the final analysis.
Three of the four SNPs did not show evidence of asso-
ciation, and were subsequently excluded (rs752237,
rs736289 and rs4239576) from further analysis leaving
41 SNPs for the final analyses. In the cases of these
three variants the deviation from HWE was likely due to
technical problems in genotyping.
Using an allelic c2 test of association, eight SNPs in
three genes, CD22 (2 SNPs), PEPD (5 SNPs), and
HAMP (1 SNP), were identified as being nominally asso-
ciated with AAA (p < 0.05; Table 2). When tested for
genotypic association using logistic regression, six of
these SNPs were nominally associated, two were not
associated, and an additional SNP in GPI was identified
(Table 2). Although not significantly associated, SNPs in
NFKBID did approach nominal significance (p < 0.10)
by this test. In Table 2 we also present the FDR-values
for the LRT statistics. Only the association with
rs7248389 in PEPD remained significant when correct-
ing for multiple testing.
Since there were multiple associated SNPs in PEPD
and CD22, the LD structure of the genotyped SNPs in
each gene was examined using LD plots (Additional file
7, Figure S1 and Additional file 8, Figure S2).
To identify population-specific effects, allelic association
was evaluated in the Canadian and Belgian subpopulations
separately (Table 2). For a majority of the SNPs identified
above, evidence of association was stronger in the Cana-
dian subpopulation. Four SNPs (rs2267574, rs7248389,
rs889140, and rs7251432) were nominally associated in
33 35 37
CEPBA
CEPBG
PEPD
GPI
Mb
HAMP CD22
NFKBID
HCST
TYROBP
Figure 1 Map of relative positions of candidate genes in the AAA1 linkage interval. The relative positions of the nine candidate genes
studied are shown above (plus strand) or below (minus strand) the black scale bars depending on the direction of transcription. The positions
of genotyped SNPs are indicated at the top as gray lines.
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the Canadian subpopulation, but only one of these
(rs7248389) showed evidence for association in the Belgian
subpopulation. One associated SNP located in PEPD
(rs7248389) showed nominal deviation from HWE. All
nominally associated SNPs and their p-values for the dif-
ferent tests are summarized in Table 2.
Haplotypic tests of association were also performed on
SNPs in CD22 and PEPD. Using a sliding window of
five consecutive SNPs, nominally significant haplotypic
association (p = 0.0026) was identified in the region of
PEPD at the SNPs rs10500265-rs6510383-rs7248389-
rs7250833-rs2241380 (Table 3). Nominally significant
Table 1 Functional positional candidate genes studied by genetic association
Symbol GO Category KEGG Pathway SNP (N) AAA Exp Cont Exp Diff Score1
PEPD NA NA 25 1300 957 10.52
CEBPG immune response; others NA 2 222 252 -3.27
CEBPA myeloid cell differentiation NA 16 630 118 31.322
GPI humoral immune response NA 5 1136 759 11.57
HAMP immune response; others NA 1 136 ND 13.57
CD22 immune response; others B-cell receptor signaling pathway 4 578 ND 16.17
NFKBID inflammatory response NA 1 22.4 ND 23.802
TYROBP cellular defense response natural killer cell mediated cytotoxicity 1 4973 801 41.152
HCST NA natural killer cell mediated cytotoxicity 0 736 148 33.442
Nine genes were identified within the AAA linkage intervals on chromosome 19 (AAA1 locus) with annotated GO or KEGG functions relevant to AAA. mRNA
expression levels for each gene in both AAA and control abdominal aortic tissue, as well as a score indicating the differences in expression levels (Diff score),
were obtained from our previously published work, details of which can be found in [30] and the microarray data can be obtained at the Gene Expression
Omnibus (GEO) database (Series# GSE7084; http://www.ncbi.nlm.nih.gov/geo/).
1The Diff Score is generated using a custom algorithm from Illumina. A Diff Score of 13 corresponds to an approximate p value of 0.05.
2Significantly different between AAA and control tissues after correction for multiple testing (FDR <0.05).
Chr, chromosome; NA, not applicable; ND, not detected; Exp, Expression; Cont, Control.
Table 2 Genetic association study results for SNPs with nominal p < 0.05
SNP Gene Alleles
(Minor/Major)
MAF (Cases; Controls)
c2 test P-value
LRT
Combined Canadian Belgian P-value FDR
rs7248389 PEPD T/C 0.395; 0.478 0.404; 0.493 0.379; 0.469
0.0009 0.0220 0.0084 0.001 0.037
rs8891401 PEPD C/T 0.326; 0.395 0.328; 0.411 0.320; 0.386
0.0043 0.0248 0.0513 0.0025 0.088
rs2267574 CD22 A/T 0.105; 0.147 0.106; 0.180 0.110; 0.129
0.0112 0.0047 0.4185 0.016 0.15
rs2241380 PEPD G/A 0.419; 0.362 0.436; 0.371 0.404; 0.356
0.0184 0.0831 0.1536 0.035 0.185
rs756796 CD22 A/G 0.280; 0.230 0.273; 0.222 0.289; 0.234
0.02 0.1179 0.068 0.016 0.164
rs7250833 PEPD T/C 0.332; 0.282 0.328; 0.278 0.337; 0.285
0.0317 0.1582 0.0987 0.043 0.219
rs7251432 HAMP A/G 0.511; 0.459 0.520; 0.437 0.506; 0.472
0.0361 0.0296 0.5193 0.050 0.210
rs11880064 PEPD C/T 0.415; 0.364 0.431; 0.371 0.402; 0.360
0.0367 0.1045 0.2124 0.059 0.190
rs580391 GPI A/C 0.203; 0.243 0.196; 0.245 0.218; 0.243
0.0519 0.1143 0.4012 0.038 0.237
Tests for allelic association were carried out by a c2 test for each SNP. P-values < 0.05 are shown in bold. The genotypic test of association was performed using
the general linear mixed model approach implemented in the Statistical Analysis for Genetic Epidemiology (S.A.G.E.) [35] program ASSOC, which yields the
likelihood ratio test (LRT) and the Wald statistics. Only LRT results are reported here since both LRT and Wald gave similar results. SNPs are ranked here by c2
test p-value in the combined population. In the alleles column minor allele is listed first based on the results seen in controls. For rs7251432 the minor allele was
different for cases than controls.
1SNP was out of Hardy-Weinberg equilibrium in Belgian controls.
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haplotypic association (p = 0.0065) was also identified in
two SNPs in CD22 (rs756796-rs2267574) (Table 3).
DNA sequencing of exons in candidate genes with
putative association
Three genes, CD22, CEBPG, and PEPD, were chosen for
DNA sequencing. No significantly associated SNPs were
detected within CEBPG, but it was chosen for sequen-
cing since it is in close proximity to PEPD and could
plausibly contribute to the association signal detected in
that gene. CD22 was also considered an intriguing can-
didate gene since it was expressed in AAA tissue and its
expression was not detectable in non-aneurysmal
abdominal aorta.
Since the functional consequences associated with
exon sequence changes are often easier to predict than
with intronic sequences, exon sequencing covering a
minimum of the protein coding regions of each gene
was performed. The protein coding region of CEPBG
was sequenced from the genomic DNA of 21 AAA
cases, 10 familial and 11 sporadic, and two controls.
CEBPG has a large 3’-UTR that we chose not to
sequence because of the relatively weak evidence for
association within the gene. No sequence variants were
identified within the regions sequenced and therefore no
further analysis was pursued with this gene.
PEPD contains 15 small exons that are spaced over a
large genomic distance. cDNA was used as a template for
sequencing since the spliced transcript could be covered
in only three PCR reactions. Seven sequence variants were
identified in PEPD when 21 AAA cases and two controls
were analyzed (Table 4; Figure 2A; Additional file 9, Table
S7; Additional file 10, Table S8). Six individuals showed
no variation in their PEPD sequence, 12 were heterozy-
gous for one variant, four were heterozygous for two var-
iants and one individual was homozygous for the minor
allele of one variant (Additional file 9, Table S7). Four of
the seven variants were present in only 1/23 (1/46 alleles)
individuals, one was present in 3/23 (3/46 alleles), one in
5/23 (5/46 alleles) and one in 9/23 (10/46 alleles) (Addi-
tional file 9, Table S7).
Three of the PEPD sequence variants identified were
novel, in that they were not in either the dbSNP or Cel-
era databases. Two SNPs coded for non-synonymous
amino acid changes: rs17570, which results in a leucine
to phenylalanine substitution at amino acid position
435, and a novel variant resulting in an alanine to threo-
nine substitution at amino acid 432 (Table 4).
CD22 has 14 exons and was sequenced from genomic
DNA because closer exon spacing allowed for multiple
exons to be covered in a single reaction. A total of
20 sequence variants were identified, including five novel
variants when analyzing 22 AAA cases and 3 controls
(Table 5; Figure 2B; Additional file 11, Table S9; Addi-
tional file 12, Table S10). Five variants were in the protein-
coding region, including three coding for non-synonymous
amino acid substitutions, and six were found within the
3’-UTR. All but one of the 25 individuals were heterozy-
gous for at least one sequence variant. Two individuals
showed a high degree of variability and were heterozygous
for seven variants (Additional file 11: Table S9).
Three of the sequence variants identified in the CD22
were non-synonymous (R > K, R > G and G > D) amino
acid changes (Table 5). Two of the three were very rare
(MAF = 0.02), whereas one (rs10406069) had a MAF =
0.104. We tested this variant for genetic association in our
case-control set, but found no differences in the allele or
genotype frequencies between cases and controls.
Predicted functional changes
Several in silico analyses were used to predict whether
any of the observed sequence changes might alter
Table 3 Significantly associated haplotypes in PEPD and CD22 genes
Gene and SNPs in the haplotype Alleles Haplotype Haplotype
Frequency in cases Frequency in controls OR [95% CI] P-value
PEPD
[CTTCA] 0.328 0.367 Reference
rs10500265 C/G [CTCCA] 0.136 0.154 1.049 [0.761, 1.445]
rs6510383 C/T [CTTCG] 0.066 0.068 1.062 [0.687, 1.644]
rs7248389 C/T [CCCCA] 0.115 0.096 1.422 [0.997, 2.028] 0.0026
rs7250833 C/T [CTCCG] 0.021 0.013 1.872 [0.745, 4.706]
rs2241380 A/G [GCCTG] 0.095 0.075 1.512 [1.020, 2.242]
[CTCTG] 0.226 0.188 1.435 [1.087, 1.894]
CD22
rs756796 A/G [GA] 0.105 0.147 0.716 [0.528,0.971]
rs2267574 A/T [GT] 0.615 0.623 Reference 0.0065
[AT] 0.280 0.230 1.253 [0.995, 1.577]
The most common haplotype was used as a reference (OR of 1) and the other haplotypes were compared to that.
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protein function or regulation of gene expression. To
assess the potential effect of non-synonymous amino
acid substitutions, each sequence variant was analyzed
with the SIFT algorithm, which predicts whether
amino acid changes will not be tolerated. SIFT pre-
dicted that all five amino acid substitutions coded by
the sequence variants identified in CD22 and PEPD
would be tolerated. Structural modeling of PEPD
demonstrated that the identified amino acid substitu-
tions A432T and L435F, resided in close proximity in
a region that appeared to tolerate structural changes
(not shown).
The 3’-UTR of many genes acts as a binding site for
miRNAs in post-transcriptional gene regulation [42]. To
find out if any of the six sequence variants identified in the
3’-UTR of CD22 might interrupt miRNA binding,
Table 4 Sequence changes detected by cDNA sequencing of PEPD
Chr. Pos. (Build 37)1 Gene Feature Allele Change SNP Identifier MAF (Caucasian)2 mRNA Position Amino Acid Residue Change3
1 33,953,912 Exon 9 T- > C rs3745969 0.063 793 220 Y- > Y
2 33,902,652 Exon 11 T- > C rs74988985 0.021 877 248 G- > G
3 33,882,255 Exon 13 C- > T 0.021 1231 366 H- > H
4 33,882,222 Exon 13 C- > T rs17569 0.104 (0.155) 1264 377 H- > H
5 33,878,845 Exon 14 G- > A 0.021 1427 432 A- > T
6 33,878,837 Exon 14 C- > T rs17570 0.229 (0.246) 1436 435 L- > F
7 33,878,340 Exon 15 G- > T 0.021 1525 464 L- > L
1Chromosomal position obtained from the National Center for Biotechnology Information (NCBI).
2MAF calculated for each SNP from sequencing data on 23 individuals presented in the current study. MAFs in parentheses are from HapMap CEU or other
Caucasian population available at the NCBI website.
3Single letter amino acids codes are used in Residue Change column.
Chr. Pos., Chromosomal position; MAF, minor allele frequency.
For details, see Additional file 9, Table S7 and Additional file 10, Table S8.
Figure 2 Sequence variants identified by candidate gene sequencing. Variants in PEPD (A) and CD22 (B) plotted to show their relative
chromosomal positions and positions relative to gene features. Exons are indicated by the boxes above the x-axis. PEPD is transcribed right to
left (minus strand) and CD22 is transcribed left to right (plus strand). Chromosomal coordinates are in kilobase pairs (kb).
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predicted miRNA binding sites were obtained from Micro-
Cosm database. We found no evidence that the variants
changed the binding sites of any miRNAs (not shown).
CD22 and PEPD proteins are expressed in aortic wall
Protein expression of CD22 and PEPD in the aorta was
confirmed by immunohistochemical staining of paraffin-
embedded tissue sections of AAA and control abdom-
inal aorta (Figures 3 and 4). Staining demonstrated
expression of PEPD protein in both AAA and control
sections; expression was observed in fibroblasts and
myofibroblasts in the media-adventitia border in both
aneurysmal and non-aneurysmal tissue samples. Consis-
tent with previous observations [43-45], staining for
CD22 protein showed an expansion of lymphocytes in
AAA tissue as compared with non-aneurysmal aorta.
Discussion
Strong evidence of linkage exists on chromosome 19 in
the AAA1 locus [15,16], but no specific risk loci have
yet been discovered. We identified nine functional posi-
tional candidate genes within this interval for further
study by genetic association. Two of these, PEPD and
CD22, showed evidence of nominal association in multi-
ple SNPs, although only one SNP remained significant
after correction for multiple testing. Additionally,
significant five- and two-SNP haplotypes were identified
for PEPD and CD22, respectively.
Evidence of association in PEPD and CD22, was of
considerable interest. Based on gene function, gene
expression, and protein expression, these genes are plau-
sible candidates for contributing to the risk of develop-
ing an AAA. The role of PEPD in collagen metabolism
makes it a strong functional candidate for AAA.
Although it is unlikely that complete loss of PEPD func-
tion alters AAA risk, given that it results in the severe
phenotype of prolidase deficiency, polymorphisms that
alter PEPD activity could contribute to AAA formation,
particularly if they resulted in increased enzymatic activ-
ity [46]. Increased PEPD activity has been associated
with increased collagen production, both in in vitro
experiments [21,47] and in keloid scars [48]. Excess col-
lagen production is observed in AAA tissue [49], and
has been suggested to contribute to weakening of the
aneurysm wall [50]. PEPD is also regulated by several
mechanisms relevant to AAA pathogenesis. Nitric oxide,
which may contribute to AAA formation [51], upregu-
lates PEPD activity [47]. Similar to other metallopro-
teases, PEPD activity is sensitive to doxycycline [52], a
tetracycline antibiotic with anti-inflammatory properties
that have been studied for their therapeutic potential in
AAA [53-56]. Estrogen can regulate PEPD in vitro
Table 5 Sequence changes detected by CD22 exon sequencing
Chr. Pos. (Build 37) Gene Feature Allele Change SNP Identifier MAF (Caucasian) mRNA Position Amino Acid Residue Change
1 35,823,999 Intron 3 C- > T rs881456 0.021 (0.000)
2 35,824,019 Intron 3 C- > G rs10419538 0.104 (0.181)
3 35,829,381 Intron 6 A- > G rs7248108 0.042 (0.042)
4 35,831,986 Exon 7 C- > T rs25677 0.042 (0.000) 1529 484 C- > C
5 35,832,381 Exon 8 G- > A 0.021 1721 548 R- > K
6 35,832,886 Intron 9 T- > A 0.021
7 35,835,940 Intron 10 C- > T rs45453699 0.313
8 35,836,512 Exon 12 A- > G 0.021 2293 739 R- > G
9 35,836,530 Exon 12 G- > A rs10406069 0.104 (0.292) 2311 745 G- > D
10 35,836,600 Exon 12 C- > A rs34826052 0.042 2381 768 P- > P
11 35,837,148 Intron 13 G- > A hCV25603572 0.021 (0.05)
12 35,837,150 Intron 13 C- > T 0.021
13 35,837,327 Intron 13 C- > T rs58156121 0.063
14 35,837,428 Intron 13 G- > A rs12985354 0.208 (0.383)
15 35,837,694 3’-UTR C- > T rs73031792 0.250 2715
16 35,837,705 3’-UTR A- > G rs35529786 0.167 2726
17 35,837,724-5 3’-UTR GC I/D1 rs34472317 0.042 2745-6
18 35,837,813 3’-UTR C- > T 0.042 2834
19 35,837,846 3’-UTR C- > T rs16970255 0.042 (0.000) 2867
20 35,838,076 3’-UTR C- > T rs3088063 0.042 (0.055) 3097
1Variant allele is GC insertion.
For definitions, see footnote to Table 4.
For details, see Additional file 11, Table S9 and Additional file 12, Table S10.
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[57,58], an interesting observation given that AAA is six
times more common in men than women [1]. Finally,
increased serum activity of PEPD has been associated
with diseases such as asthma [59], coronary artery dis-
ease [60], and fatty liver disease [61].
CD22 is a sialic-acid binding protein found on cells of
B-cell lineage. It can inhibit signaling through the B-cell
receptor [22], suggesting that impairment of gene func-
tion might lead to dysregulation of the immune
response and either autoimmune disease or increased
inflammation. Supporting this hypothesis is evidence of
a role for CD22 in systemic sclerosis; anti-CD22 autoan-
tibodies contribute to systemic sclerosis pathogenesis
[62] and there is evidence of association between a SNP
in CD22 and limited cutaneous systemic sclerosis [23].
Systemic sclerosis is characterized by immune infiltra-
tion and excessive fibrosis, both of which are observed
in AAA subtype known as inflammatory AAA [63].
Given that patients with inflammatory AAA are more
likely to have a positive family history [64], CD22 poly-
morphisms could contribute to AAA risk. On the other
hand, Cd22 knockout mice display a minimal phenotype
with no evidence of increased autoimmune disease [22].
It is plausible, however, that polymorphisms in CD22
could modulate the immune response in an inflamma-
tory disease such as AAA through changes in the
amount of CD22 protein produced in a cell or an altera-
tion of the gene’s function in B-cell signalling.
Exon sequencing of PEPD and CD22 showed that
both have polymorphic coding regions. Polymorphisms
Figure 3 Immunohistochemical staining of CD22 demonstrates expression in AAA tissue associated lymphocytes. Immunohistochemical
staining using a commercially available specific antibody against CD22 was performed on formalin-fixed paraffin embedded tissue sections of
non-aneurysmal abdominal aorta (A) and AAA (B, C, D). Negative control staining with non-immune serum showed no staining (data not
shown). Images are centered on lymphocytes (small round cells with sparse cytoplasm) primarily seen in the adventitial layer. The adjacent
media is indicated with an asterisk. Positive staining appears reddish-brown with hematoxylin counterstaining in blue.
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that did not result in amino acid substitution or changes
to the 3’-UTR were not considered further, since their
functional effects are difficult to predict. After investiga-
tion for predicted functional consequences, all of the
sequence changes identified in the coding regions or
3’-UTR of CD22 and PEPD appeared to be tolerated.
One limitation of this study was that the sample size
used for genetic association provided only modest power.
Although we did observe nominal association in several
genes, only one remained significant after correction for
multiple testing. Our results should, however, be consid-
ered in light of the prior evidence of linkage on chromo-
some 19q13. While this evidence does indicate the
presence of variants contributing to AAA risk at this
locus, the differences between linkage and association do
not make identification of associated variants a given.
Linkage is tolerant of allelic heterogeneity, whereas a var-
iant must be sufficiently common to be detected by asso-
ciation. Therefore, a biologically relevant variant in a
linked region may exhibit either weak association, as we
observed, or no evidence of association (extensive allelic
heterogeneity). Furthermore, if there is also locus hetero-
geneity in genetic risk factors between populations,
increasing sample size using subjects from a different
population than that originally studied may actually
decrease the evidence of association observed. In light of
Figure 4 Immunohistochemical staining of PEPD demonstrates expression in both aneurysmal and non-aneurysmal aortic tissue.
Immunohistochemical staining using a commercially available specific antibody against PEPD was performed on formalin-fixed paraffin
embedded tissue sections of non-aneurysmal abdominal aorta (A, B) and AAA (C, D) with staining observed in medial (A) and adventitial layers
of controls and throughout the aneurysmal wall. Negative control staining with non-immune serum showed no staining (data not shown).
Regions of positive staining appear reddish-brown with hematoxylin counterstaining in blue.
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this and our observation of association at multiple SNPs
for each gene, we consider our findings for PEPD and
CD22 worth additional studies.
It is possible that the associations seen here resulted from
spurious associations or from population stratification. A
recent association study examining SNPs from the chromo-
some 19 linkage interval in the Dutch population found
several nominally associated SNPs but none remained sig-
nificant for multiple testing [65]. Interestingly, the SNP
showing the strongest evidence of association resided in
CEPBG, which is in agreement with our observation of
association in the region of CEBPG and PEPD (Figure 1).
Finally, by focusing on functional candidate genes
rather than genotyping the entire linkage region, it is
possible that linked and associated genes were over-
looked. The strategy presented here was based on redu-
cing the number of tests due to the limited power of
our sample and the increased ability to interpret associa-
tions in genes of known function. Recent technological
improvements in high-throughput sequencing provide a
potentially more efficient approach to follow-up of link-
age results [66,67]. Deep sequencing at high coverage of
linkage intervals in members of linked families has iden-
tified novel loci. For late age-at-onset diseases the lack
of complete nuclear pedigrees and inability to identify
definitively unaffected individuals, will reduce the
approach to affected relative pair sequencing.
Conclusions
In the present study nine functional positional candidate
genes on AAA1 locus on chromosome 19 were investi-
gated. Two of the genes, CD22 and PEPD showed mod-
est level of evidence of being involved in AAA
pathogenesis. This evidence came from a nominal asso-
ciation of SNPs residing in these genes to AAA, identifi-
cation of novel sequence changes and expression of
these proteins in aneurysmal tissue. If replicated in inde-
pendent studies, the findings provide important infor-
mation about AAA pathogenesis.
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Additional File 1: Table S1. List of all 55 SNPs chosen for the study.
Each SNP genotyped for this study ordered by chromosomal coordinate.
SNP RefSeq number, gene symbol, minor allele, chromosome 19
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separately), p-values for the allelic test for combined analysis as well as
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NCBI site.
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sequencing of CEBPG and CD22. For each sample used in sequencing,
case/control status, nationality of origin, sex and sequencing status of
CD22 and CEBPG provided in tabular format.
Additional File 3: Table S3. cDNA samples used for sequencing of
PEPD. Case/control status, nationality of origin, sex and family history of
each individual whose sample was used in the sequencing of PEPD
provided in tabular format.
Additional File 4: Table S4. PCR primer pairs for CEPBG, PEPD and
CD22. For each PCR reaction, a description of each reaction, primer pair
sequences and orientation, product sizes, annealing temperatures, and
the cycling times and magnesium chloride concentrations used provided
in tabular format.
Additional File 5: Table S5. Sequencing primers used for CEBPG,
PEPD and CD22. For each sequencing reaction, a description of the
reaction, the primer sequences and orientation, and predicted melting
points for primer provided in tabular format.
Additional File 6: Table S6. Human tissue samples used in
immunohistochemical analysis of CD22 and PEPD. Donor age, sex,
case/control status and control cause of death if known.
Additional File 7: Figure S1. Linkage disequilibrium (LD) plots of
genotyped SNPs in CEBPG and PEPD for cases (A) and controls (B)
separately. LD at the CEBPG/PEPD locus plotted separately for cases and
controls using r2 as the statistic. Approximate locations of genes and
SNPs were plotted along the x-axis above plots. Nominally associated
SNPs are indicated with an asterisk.
Additional File 8: Figure S2. LD plots of genotyped SNPs in CD22
for cases (A) and controls (B) separately. LD at the CD22 locus plotted
separately for cases and controls using r2 as the statistic. Approximate
location of CD22 and SNPs were plotted along the x-axis above plots.
Nominally associated SNPs are indicated with an asterisk.
Additional File 9: Table S7. PEPD sequence changes by sample
number. Table showing genotype at each sequence variant detected by
sequencing in each individual sequenced. Sample numbers refer to
Additional file 3, Table S3, and sequence change number refers to
Table 4.
Additional File 10: Table S8. Flanking sequences of the PEPD
sequence variants. Gene feature, 15 bp flanking sequences and SNP
identifier, if available, for each sequence variant.
Additional File 11: Table S9. CD22 sequence changes by sample
number. Table showing genotype at each sequence variant detected by
sequencing in each individual sequenced. Sample numbers refer to
Additional file 2, Table S2, and sequence change number refers to
Table 5.
Additional File 12: Table S10. Flanking sequences of the CD22
sequence variants. Gene feature, 15 bp flanking sequences and SNP
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